Description
TEVIMBRA (tislelizumab-jsgr) is an intravenous injection used as an immunotherapy drug that blocks programmed death receptor-1 (PD-1) to help the immune system fight certain cancers. Manufactured by BeOne Medicines USA, Inc., it's available as a 10 mg/mL solution concentrate, approved under BLA761232 and marketed since March 2024. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Tislelizumab-jsgr | HTML | Access the FDA dataset for Tislelizumab-jsgr — ANDA 761232 submitted by Mylan Institutional LLC | Open resource |